ScinoPharm to construct high potency cytotoxic injectable plant facility

The new facility suitable for production of oncological injectable products will be built at the company’s premise at the Tainan Science Park.

ScinoPharm president and CEO Jo Shen said that by expanding into the field of oncological injectable formulation, ScinoPharm will be able to provide a vertically integrated, one-stop-shop service for its existing API customers.

"Many international generic customers of ours have been eagerly searching for partners who can provide a high quality and stable supply of oncological injectable drug products not to mention meet GMP requirements. We are excited to be able to fill this critical requirement," Dr. Shen added.

The new plant will facilitate space for R&D, quality control, washing, sterilization, manufacturing, filling, lyophilization, packaging, and storage.

A line for the oncological production at the new facility will be capable for producing liquid vials as well as lyophilized vials.

The company expects to begin designing and construction of the plant in the second half of 2012, with completion expected in 2014.